Close Menu

NEW YORK (GenomeWeb) – A comparison of commercially available multigene breast cancer recurrence signatures suggests that some tests may be better than others at assessing which patients are at risk for late distant recurrence, which could be impacting oncologists' ability to guide appropriate treatment decisions for patients. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.